Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,089 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Registries and Cohorts to Accelerate Early Phase Alzheimer's Trials. A Report from the E.U./U.S. Clinical Trials in Alzheimer's Disease Task Force.
Aisen P, Touchon J, Andrieu S, Boada M, Doody R, Nosheny RL, Langbaum JB, Schneider L, Hendrix S, Wilcock G, Molinuevo JL, Ritchie C, Ousset PJ, Cummings J, Sperling R, DeKosky ST, Lovestone S, Hampel H, Petersen R, Legrand V, Egan M, Randolph C, Salloway S, Weiner M, Vellas B. Aisen P, et al. Among authors: ritchie c. J Prev Alzheimers Dis. 2016;3(2):68-74. doi: 10.14283/jpad.2016.97. J Prev Alzheimers Dis. 2016. PMID: 29210442
A phase II trial of tideglusib in Alzheimer's disease.
Lovestone S, Boada M, Dubois B, Hüll M, Rinne JO, Huppertz HJ, Calero M, Andrés MV, Gómez-Carrillo B, León T, del Ser T; ARGO investigators. Lovestone S, et al. J Alzheimers Dis. 2015;45(1):75-88. doi: 10.3233/JAD-141959. J Alzheimers Dis. 2015. PMID: 25537011 Clinical Trial.
Effect of Alzheimer's disease risk and protective factors on cognitive trajectories in subjective memory complainers: An INSIGHT-preAD study.
Teipel SJ, Cavedo E, Lista S, Habert MO, Potier MC, Grothe MJ, Epelbaum S, Sambati L, Gagliardi G, Toschi N, Greicius MD, Dubois B, Hampel H; INSIGHT-preAD study group; Alzheimer Precision Medicine Initiative (APMI). Teipel SJ, et al. Alzheimers Dement. 2018 Sep;14(9):1126-1136. doi: 10.1016/j.jalz.2018.04.004. Epub 2018 May 21. Alzheimers Dement. 2018. PMID: 29792873
Applicability of in vivo staging of regional amyloid burden in a cognitively normal cohort with subjective memory complaints: the INSIGHT-preAD study.
Sakr FA, Grothe MJ, Cavedo E, Jelistratova I, Habert MO, Dyrba M, Gonzalez-Escamilla G, Bertin H, Locatelli M, Lehericy S, Teipel S, Dubois B, Hampel H; for the INSIGHT-preAD study group; Alzheimer Precision Medicine Initiative (APMI). Sakr FA, et al. Alzheimers Res Ther. 2019 Jan 31;11(1):15. doi: 10.1186/s13195-019-0466-3. Alzheimers Res Ther. 2019. PMID: 30704537 Free PMC article.
The Alzheimer Precision Medicine Initiative.
Hampel H, Vergallo A, Perry G, Lista S; Alzheimer Precision Medicine Initiative (APMI). Hampel H, et al. J Alzheimers Dis. 2019;68(1):1-24. doi: 10.3233/JAD-181121. J Alzheimers Dis. 2019. PMID: 30814352 Review.
Precision prevention of Alzheimer's and other dementias: Anticipating future needs in the control of risk factors and implementation of disease-modifying therapies.
Frisoni GB, Molinuevo JL, Altomare D, Carrera E, Barkhof F, Berkhof J, Delrieu J, Dubois B, Kivipelto M, Nordberg A, Schott JM, van der Flier WM, Vellas B, Jessen F, Scheltens P, Ritchie C. Frisoni GB, et al. Among authors: ritchie c. Alzheimers Dement. 2020 Oct;16(10):1457-1468. doi: 10.1002/alz.12132. Epub 2020 Aug 20. Alzheimers Dement. 2020. PMID: 32815289
1,089 results